Adherence to statins and its impact on clinical outcomes: a retrospective population-based study in China
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Background: While the benefit of adherence to statins on clinical outcomes has been proved, this benefit may be heterogeneous among patients who initiated statins for primary or secondary prevention purpose. This study aimed to investigate the impact of statin adherence on clinical outcomes among patients who initiated statins for primary and secondary prevention in China. Methods: Adult patients in Tianjin Urban Employee Basic Medical Insurance database who initiated ≥2 prescriptions of statins from 2012 through 2013 were included and grouped into primary and secondary prevention subgroups according to their cardiovascular diseases (CVD) history during the prior 12-month baseline period. Proportion of days covered (PDC) was used to measure statin adherence in the initial 12-month follow-up. Clinical outcomes were measured by the incidence of major adverse cardiovascular events (MACE) during the 13th–24th months follow-up, and were compared between the patients with PDC ≥ 0.5 and patients with PDC < 0.5 using Cox regression models in primary and secondary prevention subgroups. Sensitivity analyses were conducted in propensity score matched groups. Results: 99,655 patients were finally included. The mean (SD) PDC was 0.19 (0.15) in primary prevention subgroup (N = 34,372), with 5.4% patients had PDC ≥ 0.5. The patients with PDC ≥ 0.5 had a 37% reduced risk of MACE compared with patients with PDC < 0.5 (Unadjusted incidence rate of MACE: 1.1% vs. 1.4%; all-adjusted HR = 0.63; 95% CI, 0.41–0.98). While, no significant difference was observed in the secondary prevention subgroup (N = 65,283) between patients with PDC ≥ 0.5 and patients with PDC < 0.5 (Unadjusted incidence rate of MACE: 4.6% vs. 2.8%; all-adjusted HR = 1.08, 95% CI, 0.92–1.28). These findings were confirmed by the sensitivity analyses in propensity score matched groups. Conclusions: Statin adherence was very poor in China, and statin adherence is associated with decreased risk of MACE in patients for primary prevention, while further exploration is needed for secondary prevention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies show that combining strategies such as behaviour, education, and reminders can improve statin adherence by as much as 22% compared to isolated interventions.85,91,92”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Effect of Statins on Risk of Coronary Disease: A Meta-analysis of Randomized Controlled Trials
LaRosa, J. C., He, J., & Vupputuri, S. (1999) · JAMA · doi:10.1001/jama.282.24.2340 · Cited by 1,246
Jellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., Grunberger, G., Guerin, C. K., Bell, D. S. H., Mechanick, J. I., et al. (2017) · Endocrine Practice · doi:10.4158/ep171764.appgl · Cited by 1,094
Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences
Chowdhury, R., Khan, H., Heydon, E., Shroufi, A., Fahimi, S., Moore, C., Stricker, B., Mendis, S., Hofman, A., Mant, J., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht295 · Cited by 931
Research works printed but not linked: 24
- Editor committee of Chinese guidelines on prevention and treatment of dyslipidemia in adults. Chinese guidelines on prevention and treatment of dyslipidemia in adults in 2016. Chin J Circ. 2016;31(10):937–53 Chinese.
- Writing Group of China Guidelines for Cardiovascular Disease Prevention (2017), Editorial Board of China Journal of Cardiovascular Disease. Chinese guideline on the prevention of cardiovascular disease (2017). Chin J Circ. 2018;46(1):10–25 Chinese.
- Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–78. · DOI · Paper page
- Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial–lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149–58. · DOI · Paper page
- Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685–96. · DOI · Paper page
- Chen PS, Cheng CL, Kao Yang YH, Li YH. Statin adherence after ischemic stroke or transient ischemic attack is associated with clinical outcome. Circ J. 2016;80(3):731–7. · DOI
- Wei L, Wang J, Tompson P, Struthers S, MacDonald TM. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart. 2002;88(3):229–33. · DOI · Paper page
- Esposti LD, Saragoni S, Batacchi P, Benemei S, Geppetti P, Sturani A, et al. Adherence to statin treatment and health outcomes in an Italian cohort of newly treated patients: results from an administrative database analysis. Clin Ther. 2012;34(1):190–9. · DOI
- Rannanheimo PK, Tiittanen P, Hartikainen J, Helin-Salmivaara A, Huupponen R, Vahtera J, et al. Impact of statin adherence on cardiovascular morbidity and all-cause mortality in the primary prevention of cardiovascular disease: a population-based cohort study in Finland. Value Health. 2015;18(6):896–905. · DOI
- Li YC, Huang WL. Effects of adherence to statin therapy on health care outcomes and utilizations in Taiwan: a population-based study. Biomed Res Int. 2015;2015:1–8.
- Simpson RJ, Mendys P. The effects of adherence and persistence on clinical outcomes in patients treated with statins: a systematic review. J Clin Lipidol. 2010;4(6):462–71. · DOI
- Bouchard MH, Dragomir A, Blais L, Bérard A, Pilon D, Perreault S. Impact of adherence to statins on coronary artery disease in primary prevention. Br J Clin Pharmacol. 2007;63(6):698–708. · DOI · Paper page
- Perreault S, Dragomir A, Blais L, Bérard A, Lalonde L, White M, et al. Impact of better adherence to statin agents in the primary prevention of coronary artery disease. Eur J Clin Pharmacol. 2009;65(10):1013–24. · DOI
- Perreault S, Ellia L, Dragomir A, Côté R, Blais L, Bérard A, et al. Effect of statin adherence on cerebrovascular disease in primary prevention. Am J Med. 2009;122(7):647–55. · DOI
- Blackburn DF, Dobson RT, Blackburn JL, Wilson TW. Cardiovascular morbidity associated with nonadherence to statin therapy. Pharmacotherapy. 2005;25(8):1035–43. · DOI · Paper page
- Slejko JF, Ho M, Anderson HD, Nair KV, Sullivan PW, Campbell JD. Adherence to statins in primary prevention: yearly adherence changes and outcomes. J Manag Care Pharm. 2014;20(1):51–7. · DOI · Paper page
- Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008;155(4):772–9. · DOI · Paper page
- Xie G, Sun Y, Myint PK, Patel A, Yang X, Li M, et al. Six-month adherence to statin use and subsequent risk of major adverse cardiovascular events (MACE) in patients discharged with acute coronary syndromes. Lipids Health Dis. 2017;16(1):155–62. · DOI
- Corrao G, Conti V, Merlino L, Catapano AL, Mancia G. Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy. Clin Ther. 2010;32(2):300–10. · DOI
- Shalev V, Chodick G, Silber H, Kokia E, Jan J, Heymann AD. Continuation of statin treatment and all-cause mortality, a population-based cohort study. Arch Intern Med. 2009;169(3):260–8. · DOI · Paper page
- Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15(9):728–40. · DOI · Paper page
- Shang P, Liu GG, Zheng X, Ho PM, Hu S, Li J, et al. Association between medication adherence and 1-year major cardiovascular adverse events after acute myocardial infarction in China. J Am Heart Assoc. 2019. https://doi.org/10.1161/JAHA.118.011793. · DOI
- Chapman RH, Yeaw J, Roberts CS. Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees. BMC Cardiovasc Disord. 2010;10(1):29–0. · DOI
- Korhonen MJ, Ruokoniemi P, Ilomäki J, Meretoja A, Helin-Salmivaara A, Huupponen R. Adherence to statin therapy and the incidence of ischemic stroke in patients with diabetes. Pharmacoepidem Dr S. 2016;25(2):161–9. · DOI
Cited by
Safety and Lipid-Lowering Efficacy of Inclisiran Monotherapy in Patients Without ASCVD
Taub, P. R., Gutierrez, A., Wewers, D., Garcia Cantu, E., Cao, H., Deck, C., Lesogor, A., Ott, D., Mena-Madrazo, J., Zang, X., et al. (2025) · JACC · doi:10.1016/j.jacc.2025.04.049 · Cited by 25
Rakhshanda, S., Briggs, N. E., Rhee, J., Rye, K.-A., Liaw, S.-T., & Jonnagaddala, J. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag175 · Cited by 6
Metadata
- Authors
- Zhao, B., He, X., Wu, J., & Yan, S.
- ORCID
- Wu, Jing
- Venue
- BMC Cardiovascular Disorders
- Published
- 2020-06-10
- Volume
- 20
- Issue
- 1
- ISSN
- 1471-2261
- Cited by
- 30
- References
- 4
- Language
- en
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adherence to statins and its impact on clinical outcomes: a retrospective population-based study in China. https://app.cochat.ai/papers/10.1186/s12872-020-01566-2
- The paper
- Zhao, B., He, X., Wu, J., & Yan, S. (2020). Adherence to statins and its impact on clinical outcomes: a retrospective population-based study in China. BMC Cardiovascular Disorders. https://doi.org/10.1186/s12872-020-01566-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.